Low-Grade Serous Ovarian Cancer Symptoms, Treatment & Care

What Is Low-Grade Serous Ovarian Cancer?

Low-grade serous ovarian cancer (LGSOC) accounts for 5-10% of epithelial ovarian cancers. It often develops from serous borderline tumors and tends to affect younger women, exhibiting an indolent (slow-growing) course. In contrast to high-grade serous ovarian cancer (HGSOC), LGSOC grows slowly, usually involves mutations in KRAS or BRAF instead of TP53, and is resistant to chemotherapy.

Symptoms and Signs of Low-Grade Serous Ovarian Cancer

Symptoms of LGSOC are similar to those of other ovarian cancers and may include bloating, early satiety, pelvic or abdominal pain, changes in urinary habits, fatigue, and alterations in bowel habits. These nonspecific symptoms often persist for more than two weeks and typically arise when the disease has reached an advanced stage at the time of diagnosis.

Causes and Risk Factors

• •Risk Factors
  Includes age (commonly in the 50s), nulliparity (never having given birth), obesity, hormone therapy, and family history.
• •Protective Factors
  Multiparity (having given birth multiple times), the use of oral contraceptives, and tubal ligation may reduce risk.
• •Genetic Basis
  Mutations such as BRAF or KRAS are involved in the progression from borderline tumors to LGSOC.

Diagnosis and Staging

The diagnosis of LGSOC typically involves the measurement of CA-125 levels, ultrasound, CT or MRI scans, and a surgical biopsy to confirm low-grade histology. Staging is done according to the FIGO system during comprehensive surgery, which places an emphasis on assessing the peritoneum. Early detection remains a challenge due to the absence of routine screening.

Treatment Options for LGSOC

Get Your Free Cancer Diet Plan & Report Analysis Now on WhatsApp

Talk to experts. Understand your reports. Get a personalized diet plan — all free to start.

Get My Free Plan on WhatsApp

India's First Cancer Care Management Platform

Free to start•Secure & private•No app download needed

• •Cytoreductive Surgery
  The primary treatment option aimed at achieving no residual disease.
• •Chemotherapy
  Platinum-based chemotherapy is often used despite a low response rate of 4-11%.
• •Targeted Therapies
  MEK inhibitors (e.g., binimetinib, trametinib) effectively target the BRAF and KRAS pathways.
• •Hormonal Treatments
  Options such as tamoxifen and letrozole are used to manage the disease.
• •Maintenance Strategies
  Long-term care plans to help improve disease control and delay progression.

Prognosis and Survival Rates

LGSOC is associated with a better prognosis, boasting a 5-year survival rate of 75% and a 10-year survival rate of 70%, compared to HGSOC's 40% and 26%. The median overall survival for LGSOC is between 99 and 110 months, owing to its slower progression.

Factors Influencing Prognosis

Complete surgical resection to achieve no visible residual disease significantly enhances survival rates. Additionally, factors such as the stage of cancer, resistance to chemotherapy, obesity, and molecular subtype play important roles in determining outcomes.

Why Choose Everhope for LGSOC Care

Everhope Oncology specializes in precision profiling for therapies targeting BRAF and KRAS mutations, along with integrated nutrition programs that enhance tolerance to hormonal treatments.